In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews (04/2011)

Executive Summary

A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Advancing the Technological Frontier in AAA Repair," features profiles of Altura Medical, Aptus Endosystems, Endoluminal Sciences and SOVAmed. Plus these Start-Ups Across Health Care: ACT Biotech, Ausio Pharmaceuticals, CureFAKtor Pharmaceuticals, Harbor MedTech and Insituvue.

You may also be interested in...



Altura Medical Inc.

Altura Medical is developing a percutaneous, low-profile endovascular stent-graft for the treatment of AAAs designed to eliminate some of the major issues associated with conventional endograft procedure safety, efficacy and complexity. The company's plan is to provide a flexible, off-the-shelf, ultra-low profile device with an industry-first 12 French inside diameter. The Altura system may be placed routinely in the cath lab as an outpatient procedure, and in more difficult AAA anatomies that are usually referred for open surgery, including those patients with short necks or smaller, tortuous iliac arteries.

Advancing The Technological Frontier In AAA Repair

Start-ups are striving to expand the patient pool for endovascular abdominal aortic aneurysm repair - and get in on one of the highest-growth device market opportunities. In this issue, we profile Altura Medical, Aptus Endosystems, Endoluminal Sciences and SOVAmed.

Aptus Endosystems Inc.

Despite notable advances in endovascular aortic aneurysm repair systems to prevent aneurysm rupture by stent-graft implantation, between 15-20% of patients eventually require secondary intervention to address endograft failures. Aptus Endosystems hopes to dramatically reduce the incidence of secondary intervention with its EVAR system: a low-profile modular endograft which uses novel stapling fixation that the company says approaches the durability of open surgery and makes minimally invasive AAA treatment an option for more patients, even those with challenging anatomy.

Related Content

Related Companies

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel